FDA: Trilipix-statin combo doesn't seem to lower heart risk

11/9/2011 | Medscape (free registration)

An FDA review of data from the ACCORD Lipid trial found no significant difference in the risk of major cardiovascular events between type 2 diabetes patients treated with Abbott Laboratories' cholesterol-lowering drug Trilipix plus simvastatin and those given only simvastatin. The finding prompted the FDA to issue a safety alert and update prescribing information for Trilipix. The agency also asked Abbott to conduct a trial looking at the medication's cardiovascular effects on statin users.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC